Juni 2015 - IOZK

Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses

2015-06-26/in International Publications, Newcastle Disease Virus /von 2015-06-26 / Mol. Ther. 2015 Oct;23(10):1630-40

Vaccination of multiple myeloma: Current strategies and future prospects

2015-06-18/in Dendritic Cells, International Publications, Multiple Myeloma /von 2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-54

Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).

2015-06-17/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)

Brain Tumor Immunotherapy: What have We Learned so Far?

2015-06-17/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-17 / Front Oncol 2015;5:98

IOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs

2015-06-15/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZK

Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model

2015-06-13/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32

Beitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift „Skriptum“

2015-06-12/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZK

Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma

2015-06-11/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2015-06-11 / Viruses 2015 Jun;7(6):2980-98

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy

2015-06-02/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2015-06-02 / Front Immunol 2015;6:271

Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.

2015-06-01/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)